{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:41:09Z","timestamp":1784130069494,"version":"3.55.0"},"reference-count":63,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,2]]},"abstract":"<jats:p>Dengue is one of the most problematic vector-borne diseases in the Philippines, with an estimated 842,867 cases resulting in medical costs of $345 million U.S. dollars annually. In December 2015, the first dengue vaccine, known as chimeric yellow fever virus\u2013dengue virus tetravalent dengue vaccine, was approved for use in the Philippines and is given to children 9 years of age. To estimate the cost-effectiveness of dengue vaccination in the Philippines, we developed an age-structured model of dengue transmission and vaccination. Using our model, we compared two vaccination scenarios entailing routine vaccination programs both with and without catch-up vaccination. Our results indicate that the higher the cost of vaccination, the less cost-effective the dengue vaccination program. With the current dengue vaccination program that vaccinates children 9 years of age, dengue vaccination is cost-effective for vaccination costs up to $70 from a health-care perspective and up to $75 from a societal perspective. Under a favorable scenario consisting of 1 year of catch-up vaccinations that target children 9\u201315 years of age, followed by regular vaccination of 9-year-old children, vaccination is cost-effective at costs up to $72 from a health-care perspective and up to $78 from a societal perspective. In general, dengue vaccination is expected to reduce the incidence of both dengue fever and dengue hemorrhagic fever \/dengue shock syndrome. Our results demonstrate that even at relatively low vaccine efficacies, age-targeted vaccination may still be cost-effective provided the vaccination cost is sufficiently low.<\/jats:p>","DOI":"10.4269\/ajtmh.16-0194","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T03:04:06Z","timestamp":1473217446000},"page":"1137-1147","source":"Crossref","is-referenced-by-count":33,"title":["Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines"],"prefix":"10.4269","volume":"95","author":[{"given":"Eunha","family":"Shim","sequence":"first","affiliation":[{"name":"Department of Mathematics, Soongsil University, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"ref1","series-title":"PLoS Negl Trop Dis","first-page":"e0004337","article-title":"Incidence of dengue virus infection in adults and children in a prospective longitudinal cohort in the Philippines","volume":"10","author":"Alera","year":"2016"},{"key":"ref2","series-title":"PLoS Negl Trop Dis","first-page":"e2055","article-title":"Economic and disease burden of dengue in southeast Asia","volume":"7","author":"Shepard","year":"2013"},{"key":"ref3","series-title":"Am J Trop Med Hyg","first-page":"360","article-title":"Economic cost and burden of dengue in the Philippines","volume":"92","author":"Edillo","year":"2015"},{"key":"ref4","series-title":"Biotechnol Adv","first-page":"239","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011"},{"key":"ref5","series-title":"Expert Rev Vaccines","first-page":"1","article-title":"Current issues in the economics of vaccination against dengue","volume":"15","author":"Tozan","year":"2016"},{"key":"ref6","series-title":"Sanofi Pasteur's Dengue Vaccine Approved in the Philippines","author":"Sanofi Pasteur","year":"2015"},{"key":"ref7","series-title":"Nat Biotechnol","first-page":"8","article-title":"Mexico dengue vaccine first","volume":"34","year":"2016"},{"key":"ref8","series-title":"Lancet","first-page":"1358","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014"},{"key":"ref9","series-title":"Vaccine","first-page":"1643","article-title":"Protective and immunological behavior of chimeric yellow fever dengue vaccine","volume":"34","author":"Halstead","year":"2016"},{"key":"ref10","series-title":"Am J Trop Med Hyg","first-page":"910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007"},{"key":"ref11","series-title":"J Infect Dis","first-page":"1026","article-title":"Reduced risk of disease during postsecondary dengue virus infections","volume":"208","author":"Olkowski","year":"2013"},{"key":"ref12","series-title":"Epidemiol Infect","first-page":"1276","article-title":"The introduction of dengue vaccine may temporarily cause large spikes in prevalence","volume":"143","author":"Pandey","year":"2015"},{"key":"ref13","series-title":"Adv Virus Res","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003"},{"key":"ref14","series-title":"Proc Natl Acad Sci USA","first-page":"2238","article-title":"Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever","volume":"105","author":"Nagao","year":"2008"},{"key":"ref15","series-title":"J Theor Biol","first-page":"337","article-title":"Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue","volume":"242","author":"Adams","year":"2006"},{"key":"ref16","series-title":"Vaccine","first-page":"5860","article-title":"Models of the impact of dengue vaccines: a review of current research and potential approaches","volume":"29","author":"Johansson","year":"2011"},{"key":"ref17","series-title":"Am J Trop Med Hyg","first-page":"489","article-title":"A simulation model of the epidemiology of urban dengue fever: literature analysis, model development, preliminary validation, and samples of simulation results","volume":"53","author":"Focks","year":"1995"},{"key":"ref18","series-title":"Proc Natl Acad Sci USA","first-page":"11802","article-title":"Ecological and immunological determinants of dengue epidemics","volume":"103","author":"Wearing","year":"2006"},{"key":"ref19","series-title":"Bull Math Biol","first-page":"2263","article-title":"Threshold conditions for a non-autonomous epidemic system describing the population dynamics of dengue","volume":"68","author":"Coutinho","year":"2006"},{"key":"ref20","series-title":"Proc Natl Acad Sci USA","first-page":"790","article-title":"The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens","volume":"96","author":"Ferguson","year":"1999"},{"key":"ref21","series-title":"Philos Trans R Soc Lond B Biol Sci","first-page":"757","article-title":"Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys","volume":"354","author":"Ferguson","year":"1999"},{"key":"ref22","series-title":"J Theor Biol","first-page":"18","article-title":"Instabilities in multiserotype disease models with antibody-dependent enhancement","volume":"246","author":"Billings","year":"2007"},{"key":"ref23","series-title":"Chaos","first-page":"043123","article-title":"Epidemics with multistrain interactions: the interplay between cross immunity and antibody-dependent enhancement","volume":"19","author":"Bianco","year":"2009"},{"key":"ref24","series-title":"Proc Natl Acad Sci USA","first-page":"15259","article-title":"Dynamic effects of antibody-dependent enhancement on the fitness of viruses","volume":"102","author":"Cummings","year":"2005"},{"key":"ref25","series-title":"Proc Biol Sci","first-page":"2541","article-title":"Immunological serotype interactions and their effect on the epidemiological pattern of dengue","volume":"276","author":"Recker","year":"2009"},{"key":"ref26","series-title":"Phys Rev E Stat Nonlin Soft Matter Phys","first-page":"066201","article-title":"Chaotic desynchronization of multistrain diseases","volume":"72","author":"Schwartz","year":"2005"},{"key":"ref27","series-title":"PLoS One","first-page":"e12347","article-title":"The effects of tertiary and quaternary infections on the epidemiology of dengue","volume":"5","author":"Wikramaratna","year":"2010"},{"key":"ref28","series-title":"Math Biosci","first-page":"265","article-title":"Vaccinations in disease models with antibody-dependent enhancement","volume":"211","author":"Billings","year":"2008"},{"key":"ref29","series-title":"Population Trends Philippines","first-page":"1","author":"U.S. Department of Commerce","year":"1996"},{"key":"ref30","series-title":"Vaccine","first-page":"3957","article-title":"Dengue dynamics and vaccine cost-effectiveness in Brazil","volume":"31","author":"Durham","year":"2013"},{"key":"ref31","series-title":"N Engl J Med","first-page":"1195","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015"},{"key":"ref32","series-title":"Nature","first-page":"504","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013"},{"key":"ref33","series-title":"PLoS Negl Trop Dis","first-page":"e545","article-title":"Spatial evaluation and modeling of dengue seroprevalence and vector density in Rio de Janeiro, Brazil","volume":"3","author":"Honorio","year":"2009"},{"key":"ref34","series-title":"J Theor Biol","first-page":"15","article-title":"Country- and age-specific optimal allocation of dengue vaccines","volume":"342","author":"Ndeffo Mbah","year":"2014"},{"key":"ref35","series-title":"Clin Microbiol Rev","first-page":"480","article-title":"Dengue and dengue hemorrhagic fever","volume":"11","author":"Gubler","year":"1998"},{"key":"ref36","series-title":"PLoS Negl Trop Dis","first-page":"e2126","article-title":"Challenges in the interpretation of dengue vaccine trial results","volume":"7","author":"Rodriguez-Barraquer","year":"2013"},{"key":"ref37","series-title":"Nat Rev Microbiol","first-page":"45","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016"},{"key":"ref38","series-title":"Vaccine","article-title":"Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies","author":"Coudeville","year":"2015"},{"key":"ref39","series-title":"Lancet Infect Dis","first-page":"935","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016"},{"key":"ref40","series-title":"PLoS Negl Trop Dis","first-page":"e3027","article-title":"Epidemiology of dengue disease in the Philippines (2000\u20132011): a systematic literature review","volume":"8","author":"Bravo","year":"2014"},{"key":"ref41","series-title":"Philippines Launches World's First Mass Dengue Vaccination","author":"Cerojano","year":"2016"},{"key":"ref42","series-title":"First Mass Dengue Vaccination in the World Launched in PHL","author":"Sandoval","year":"2016"},{"key":"ref43","series-title":"Vaccine","first-page":"514","article-title":"Potential opportunities and perils of imperfect dengue vaccines","volume":"32","author":"Rodriguez-Barraquer","year":"2014"},{"key":"ref44","series-title":"The Consumer Price Indexes (CPI): All Urban Consumers","author":"U.S. Bureau of Labor Statistics","year":"2007"},{"key":"ref45","series-title":"PLoS Negl Trop Dis","first-page":"e1426","article-title":"Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore","volume":"5","author":"Carrasco","year":"2011"},{"key":"ref46","series-title":"Bull World Health Organ","first-page":"429","article-title":"Quantifying the burden of disease: the technical basis for disability-adjusted life years","volume":"72","author":"Murray","year":"1994"},{"key":"ref47","series-title":"PLoS Negl Trop Dis","first-page":"e3158","article-title":"Epidemiological trends of dengue disease in Mexico (2000\u20132011): a systematic literature search and analysis","volume":"8","author":"Dantes","year":"2014"},{"key":"ref48","series-title":"PLoS Negl Trop Dis","first-page":"e1876","article-title":"Controlling dengue with vaccines in Thailand","volume":"6","author":"Chao","year":"2012"},{"key":"ref49","series-title":"Lancet","first-page":"1452","article-title":"Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study","volume":"369","author":"Anderson","year":"2007"},{"key":"ref50","series-title":"Vaccine","first-page":"1275","article-title":"Cost-effectiveness of a pediatric dengue vaccine","volume":"22","author":"Shepard","year":"2004"},{"key":"ref51","series-title":"PLoS Negl Trop Dis","first-page":"e0003547","article-title":"Economic and disease burden of dengue in Mexico","volume":"9","author":"Undurraga","year":"2015"},{"key":"ref52","series-title":"Health Policy Plan","first-page":"347","article-title":"The burden of disease, economic costs and clinical consequences of tuberculosis in the Philippines","volume":"20","author":"Peabody","year":"2005"},{"key":"ref53","series-title":"PLoS Negl Trop Dis","first-page":"e2056","article-title":"Use of expansion factors to estimate the burden of dengue in southeast Asia: a systematic analysis","volume":"7","author":"Undurraga","year":"2013"},{"key":"ref54","series-title":"Vaccine","first-page":"4025","article-title":"Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination","volume":"27","author":"Shim","year":"2009"},{"key":"ref55","series-title":"Vaccine","first-page":"6766","article-title":"The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales","volume":"30","author":"Atkins","year":"2012"},{"key":"ref56","series-title":"The World Health Report 2002: Reducing Risks, Promoting Healthy Life","author":"World Health Organization","year":"2002"},{"key":"ref57","series-title":"Am J Trop Med Hyg","first-page":"764","article-title":"Economic value of dengue vaccine in Thailand","volume":"84","author":"Lee","year":"2011"},{"key":"ref58","series-title":"Vaccine","first-page":"616","article-title":"Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission","volume":"34","author":"Orellano","year":"2016"},{"key":"ref59","series-title":"Rev Panam Salud Publica","first-page":"407","article-title":"Dengue in the Americas and southeast Asia: do they differ?","volume":"20","author":"Halstead","year":"2006"},{"key":"ref60","series-title":"PLoS Negl Trop Dis","first-page":"e3306","article-title":"Approaches to refining estimates of global burden and economics of dengue","volume":"8","author":"Shepard","year":"2014"},{"key":"ref61","series-title":"PLoS Negl Trop Dis","first-page":"e1450","article-title":"Assessing the potential of a candidate dengue vaccine with mathematical modeling","volume":"6","author":"WHO-VMI Dengue Vaccine Modeling Group","year":"2012"},{"key":"ref62","series-title":"Semin Immunol","first-page":"104","article-title":"Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil","volume":"25","author":"Barnighausen","year":"2013"},{"key":"ref63","series-title":"Clin Epidemiol","first-page":"299","article-title":"Epidemiology of dengue: past, present and future prospects","volume":"5","author":"Murray","year":"2013"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/95\/5\/article-p1137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/95\/5\/article-p1137.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/95\/5\/article-p1137.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:53:24Z","timestamp":1723067604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/95\/5\/article-p1137.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":63,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.16-0194","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]}}}